survey.jpg

 Calling all Individuals with ATTR who have Participated in Ionis’s Phase 3 Clinical Trial of Inotersen (IONIS-TTRrx): 

 

We need your help!

Take a survey to help inform drug development for ATTR

In an effort to capture your voice to guide the development of new drugs for transthyretin amyloidosis (ATTR), like Inotersen, we are conducting a survey of patients with ATTR who have participated in Ionis’s Phase 3 Clinical Trial of Inotersen (IONIS-TTRrx). The survey is intended to identify the burdens and daily impacts of ATTR prior to the Phase 3 clinical trial of Inotersen and any changes to these burdens and impacts that occurred over the course of participating in the clinical trial.  Results from this survey are planned to be summarized and shared with The Food and Drug Administration (FDA). The FDA intends to ensure that the patient voice is considered in the development and regulation of any new medications. Results will be accessible to all participants.

We kindly ask that you please take the time to fill out this important survey through the link below. It should take approximately 30 minutes and all information will be completely de-identified.
 

 
 

If you have any questions, please don’t hesitate to contact us at arc@arci.org or 617-467-5170